This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Nuvilex Technologies Recognized By The Singaporean Intellectual Property Intermediary, IPI Singapore

SILVER SPRING, Md., Jan. 17, 2013 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing natural products and cell and gene therapy solutions for the treatment of human diseases, announced today that its technologies, Cell-in-a-Box® and Bac-in-a-Box®, developed by its subsidiary Austrianova Singapore (ASPL), have been recognized and profiled by the non-profit company, Intellectual Property Intermediary Singapore (IPI Singapore).

The Cell-in-a-Box® and Bac-in-a-Box® products are proprietary living eukaryotic and bacterial cell encapsulation technological platforms developed by ASPL that can be used for a variety of living cell types. Both of them are unique platform technologies with the potential for such diverse uses as antibody production, treatment of diabetes, part of pancreatic cancer treatment regimen, treatments that employ stem cells, and for the improved use of probiotics, to name a few.

The technologies have been shown to be robust for manipulations and injections and are non-immunogenic. They can be frozen with cells inside that can be recovered years later, and they allow cells to be expanded inside the capsules as mini bioreactors. Moreover, the technology has been shown to be safe and effective for multiple diseases in animal models as well as in human clinical trials for pancreatic cancer.

IPI Singapore was launched in April 2011 as part of the Singapore Research, Innovation, and Enterprise 2015 Plan to contribute to the innovation and enterprise ecosystem in Singapore. IPI's overall aims include helping companies "identify, source, scan and assess technologies" as well as "facilitate technology transfer."

The President and CEO of Nuvilex, Dr. Robert Ryan, stated, "We are pleased IPI Singapore has recognized our technology and will provide access to information about the technologies developed by our ASPL subsidiary. We believe our Company will receive increased exposure to the business and scientific communities due to the recognition by IPI Singapore. Through this recognition and our ongoing efforts, we hope to develop multiple unique products for commercialization from the Cell-in-a-Box® and Bac-in-a-Box® technology platforms."

About Nuvilex

Nuvilex, Inc. (OTCQB: NVLX) has been a provider of all-natural products for many years and has expanded its company to become an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for research and medicine. In the biotechnology area of Nuvilex, enhanced antibody production capabilities through encapsulation, our company's offerings will include cancer, diabetes, and other clinical treatments using the company's cell and gene therapy expertise and live-cell encapsulation technology.

The Nuvilex, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13494

Safe Harbor Statement

This press release contains forward-looking statements described within the 1995 Private Securities Litigation Reform Act involving risks and uncertainties including product demand, market competition, and meeting current or future plans which may cause actual results, events, and performances, expressed or implied, to vary and/or differ from those contemplated or predicted. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, reflect events or circumstances afterward, or disclose unanticipated occurrences, except as required under applicable laws.

CONTACT: Investor Relations Contact:
         Marlin Molinaro
         Marmel Communications, LLC
         Ph: (702) 434-8692
         mmolinarofc@aol.com

Nuvilex, Inc. Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,214.42 -10.15 -0.06%
S&P 500 2,110.74 -3.12 -0.15%
NASDAQ 4,987.89 +20.7530 0.42%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs